Omnica Pharmaceuticals

Omnica is a South African biotechnology company specializing in the discovery and clinical development of standardized botanical extracts for the global pharmaceutical and nutraceutical markets. The company is best known for its pioneering work on Sceletium tortuosum, which led to the development of Zembrin, a patented extract with a unique dual mechanism of action as a PDE4 and SERT inhibitor. Omnica integrates traditional ethnobotanical knowledge with modern pharmacological validation, conducting rigorous clinical trials to support the safety and efficacy of its products. The company is also recognized for its commitment to sustainable sourcing and was a pioneer in establishing formal benefit-sharing agreements with indigenous communities. Through strategic partnerships with global distributors, Omnica's research-backed ingredients are utilized in products aimed at enhancing cognitive function and managing stress.